Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study

BACKGROUND: In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deaths in a cohort of 796,072 insured subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Paternina-Caicedo, Angel, Jit, Mark, Alvis-Guzmán, Nelson, Fernández, Juan Carlos, Hernández, José, Paz-Wilches, Justo Jesus, Rojas-Suarez, José, Dueñas-Castell, Carmelo, Alvis-Zakzuk, Nelson J., Smith, Adrian D., Hoz-Restrepo, Fernando De La
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246705/
https://www.ncbi.nlm.nih.gov/pubmed/35791428
http://dx.doi.org/10.1016/j.lana.2022.100296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246705/
https://www.ncbi.nlm.nih.gov/pubmed/35791428
http://dx.doi.org/10.1016/j.lana.2022.100296

Ejemplares similares